A weekly injection. A dramatic drop in weight. A sharp fall in heart attacks, kidney failure, and strokes. In the space of just a few years, a class of drugs called GLP-1 receptor agonists — sold under brand names like Ozempic, Wegovy, and Mounjaro — has upended how medicine treats obesity. But as 2026 opens a pivotal new chapter for these drugs, a profound question looms: who in the world will actually get to use them?
More than one billion people now live with obesity globally, a number the World Health Organization (WHO) projects could double by 2030 without decisive action. Obesity was linked to 3.7 million deaths worldwide in 2024 alone, and its economic toll is projected to reach US$3 trillion annually by 2030. GLP-1 therapies represent the most effective pharmacological breakthrough in obesity management in decades — yet currently, only about 2% of people living with obesity globally are using them. The revolution is real. The access gap is equally real.
What Are GLP-1 Receptor Agonists?
GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut after eating. It signals the brain to reduce appetite, stimulates insulin release from the pancreas, and slows gastric emptying — creating a sustained sense of fullness. GLP-1 receptor agonists are synthetic drugs that mimic this hormone, but with a much longer duration of action than the body’s own version.
First developed in the late 1980s and initially approved for type 2 diabetes, these drugs were recognised to cause substantial weight loss as a secondary effect. That observation transformed into a therapeutic revolution. Today, the three agents currently recommended by WHO for obesity treatment are liraglutide, semaglutide (injectable and now oral), and tirzepatide — a dual agonist that also targets a second gut hormone called GIP.
The Global Scale of the Problem
Obesity is not simply a matter of lifestyle choice — it is a chronic, relapsing disease shaped by genetics, environment, economics, and biology. According to the World Obesity Atlas 2025, published by the World Obesity Federation, the total number of adults living with obesity is projected to increase by more than 115% between 2010 and 2030, reaching 1.13 billion. The burden is no longer concentrated in high-income countries. Approximately 80% of people with type 2 diabetes — a condition intimately linked to obesity — now live in low- and middle-income countries (LMICs), according to the 2025 International Diabetes Federation guidelines.
Obesity drives a cascade of serious conditions: cardiovascular disease, type 2 diabetes, chronic kidney disease, fatty liver disease, obstructive sleep apnoea, and several cancers. The financial burden on health systems is immense — and growing faster than most countries can manage.
What the Latest Research Shows
The evidence for GLP-1 receptor agonists has expanded dramatically beyond weight loss. Clinical trials now confirm benefits across the entire cardiometabolic system — benefits that extend to people without diabetes.
Weight Loss
In the landmark STEP trials, weekly injectable semaglutide produced a mean body weight reduction of approximately 15% over 68 weeks in adults with obesity — a result that approaches the outcomes of bariatric surgery. Tirzepatide, studied in the SURMOUNT trials, achieved even greater weight reductions in some participants, with some losing over 20% of their body weight.
Heart Protection
The SELECT trial — published in the New England Journal of Medicine — enrolled over 17,600 adults with obesity and established cardiovascular disease, but without diabetes. It demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) with semaglutide compared to placebo over roughly three years. This was a landmark finding: it established that GLP-1 drugs protect the heart independent of their glucose-lowering effects. The SOUL trial, published in 2025, further confirmed that oral semaglutide reduced cardiovascular events by 14% in patients with type 2 diabetes and heart or kidney disease.
Kidney Protection
A secondary analysis of the SELECT trial, published in Nature Medicine in 2024, found that semaglutide was associated with a 22% reduction in composite kidney outcomes — including worsening kidney function and kidney-related death — even in people without diabetes. The FLOW trial (NEJM, 2024) showed a 24% reduction in major kidney disease events in people with type 2 diabetes and chronic kidney disease taking weekly semaglutide.
Beyond Weight and Metabolic Disease
Emerging research is now investigating the potential of GLP-1 drugs in conditions including heart failure with preserved ejection fraction, non-alcoholic fatty liver disease (now called metabolic dysfunction-associated steatohepatitis), obstructive sleep apnoea, and even neurodegenerative diseases. A meta-analysis covering 83,258 patients across 13 cardiovascular outcome trials confirmed that GLP-1 receptor agonists significantly reduced all-cause mortality, cardiovascular mortality, stroke, and composite kidney outcomes across diverse patient groups — regardless of sex, prior cardiovascular disease history, or BMI category.
The Equity Crisis: A Drug the World Cannot Afford
Despite this extraordinary evidence base, access remains catastrophically unequal. A Lancet Diabetes & Endocrinology study published in early 2026 estimated eligibility for GLP-1 drugs across 99 countries — and found that only a handful of high-income nations are realistically positioned to afford coverage for obesity management. Brand-name injectable semaglutide costs $350–$1,400 per month in many markets, requiring refrigerated storage and trained administration — conditions unavailable to billions.
The WHO published its first-ever global guideline on GLP-1 therapies for obesity in December 2025, and added these drugs to the Essential Medicines List for high-risk type 2 diabetes patients in September 2025. The WHO guideline is clear: even under the most optimistic projections, GLP-1 therapies are expected to reach fewer than 10% of those who could benefit by 2030. It called urgently for pooled procurement, tiered pricing, voluntary licensing, and local manufacturing to close this gap.
There is reason for cautious optimism. In 2026, patents for semaglutide are expiring in major markets — including India, China, Brazil, Canada, and Turkey — covering approximately 40% of the world’s population. According to a March 2026 Lancet editorial, generic injectable semaglutide could potentially be produced for as little as $28 per person-year once biosimilar competition takes hold. Oral formulations, which do not require refrigeration or complex delivery devices, further improve the outlook for low-resource settings.
What You Can Do: Practical Guidance
- If you have obesity or type 2 diabetes with cardiovascular risk: Speak with your doctor about whether a GLP-1 receptor agonist is appropriate for you. These are prescription medications requiring clinical supervision, not over-the-counter products.
- Beware counterfeit products: Since 2022, WHO has documented a sharp rise in fake GLP-1 products across nearly 60 countries. Only obtain these medications through licensed pharmacies with valid prescriptions.
- Lifestyle remains essential: WHO guidelines emphasise that GLP-1 therapies work best alongside structured dietary guidance, regular physical activity, and behavioural support — not as a standalone solution.
- Do not stop abruptly without medical advice: Clinical data consistently shows significant weight regain after discontinuing GLP-1 therapy. Any changes to treatment should be discussed with your healthcare provider.
- Advocate for access: Support policies that promote generic manufacturing, tiered pricing, and health system investment in chronic disease management in your community and country.
The India and South Asia Context
India sits at a pivotal intersection. The country carries one of the world’s largest burdens of both obesity and type 2 diabetes — with approximately 185 million adults projected to have diabetes by 2050 according to the International Diabetes Federation. South Asians also share a unique metabolic phenotype sometimes called “thin-fat obesity,” where metabolic risk is high even at lower BMI thresholds than those used in Western guidelines. The India GLP-1 receptor agonist market, valued at approximately $110 million in 2024, is projected to grow at 34.3% annually through 2030.
The critical inflection point for India arrives in 2026: the semaglutide patent is expiring, opening the door for Indian pharmaceutical companies — including Biocon, Sun Pharma, Cipla, and Dr. Reddy’s Laboratories — to develop biosimilar alternatives. Novo Nordisk has also confirmed plans to launch Wegovy in India in 2026. If biosimilar competition drives prices down substantially, India has the manufacturing capacity and pharmaceutical infrastructure to become a critical global supplier of affordable GLP-1 therapies — not just for its own 1.4 billion people, but for LMICs globally. The Indian Pharmacy Council and clinical bodies have emphasised the need for physician oversight, as self-medication and counterfeit use are already emerging concerns.
Conclusion
GLP-1 receptor agonists represent one of the most significant pharmacological advances in modern medicine. Their benefits extend well beyond weight loss — protecting the heart, kidneys, and potentially the brain. But a drug that only the wealthy can access is not a global health solution. 2026 is shaping up to be a turning point: between the WHO’s new guidelines, expiring patents in major markets, the arrival of oral formulations, and the rise of biosimilar manufacturing in India and China, the conditions for a more equitable rollout are forming. Whether that potential becomes reality will depend on policy choices, pricing decisions, and the political will of governments and international institutions. The science has delivered its answer. The world now needs to deliver equitable access.
Primary Sources:
- Chan JCN et al. Glycaemic control remains central in type 2 diabetes mellitus management: key learnings from the latest International Diabetes Federation guidelines. Diabetes Research and Clinical Practice. 2026;234:113173. PMID: 41722868
- World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. December 1, 2025. Available at: who.int
- The Lancet. Making treatment for obesity more equitable. The Lancet. March 2026. DOI: 10.1016/S0140-6736(26)00554-4
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial). N Engl J Med. 2023;389:2221–2232.
- Perkovic V et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW Trial). N Engl J Med. 2024;391(2):109–121.
- World Obesity Federation. World Obesity Atlas 2025. March 2025.
Medical Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. GLP-1 receptor agonists are prescription medications that should only be used under the supervision of a qualified healthcare professional. Always consult your doctor before starting, changing, or stopping any medication. For more information, please visit our medical disclaimer page.
Leave a Comment